George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.49
Bid: 6.02
Ask: 7.28
Change: 0.00 (0.00%)
Spread: 1.26 (20.93%)
Open: 6.49
High: 0.00
Low: 0.00
Prev. Close: 6.49
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Nov 2021 14:26

RNS Number : 0144T
Synairgen plc
19 November 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Synairgen PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Polygon Global Partners LLP

Reade Eugene Griffith

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.) v

Name

Aurora Nominee Ltd

City and country of registered office (if applicable)

London, United Kingdom

5. Date on which the threshold was crossed or reached vi:

17/11/2021

6. Date on which issuer notified (DD/MM/YYYY):

19/11/2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

15.571

0

15.571

31,350,000

Position of previous notification (if

applicable)

12.913

2.427

15.341

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00B0381Z20

0

31,350,000

0

15.571

SUBTOTAL 8. A

31,350,000

15.571%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Reade Eugene Griffith

15.571

0

15.571

Polygon Global Partners LLP

15.571

0

15.571

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Reade Eugene Griffith is the ultimate controlling natural person of Polygon Global Partners LLP, an investment manager which has investment discretion over certain funds and managed accounts.

 

Place of completion

London, United Kingdom

Date of completion

19 November 2021

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFFSLSLALIL
Date   Source Headline
28th Jun 20187:00 amRNSPositive SNG001 Biomarker Data in COPD Patients
26th Jun 20181:05 pmRNSHolding(s) in Company
22nd Jun 201811:42 amRNSResult of AGM
22nd Jun 20187:00 amRNSSynairgen Safety Data with SNG001 in COPD Patients
17th May 20187:00 amRNSPosting of Annual Report and Notice of AGM
16th Apr 20184:29 pmRNSHolding(s) in Company
6th Apr 201812:14 pmRNSGrant of Options
3rd Apr 20185:21 pmRNSHolding(s) in Company
15th Mar 20183:13 pmRNSIssue of Equity
15th Mar 20183:11 pmRNSHolding(s) in Company
15th Mar 20187:00 amRNSPreliminary results for year ended 31 Dec 2017
7th Feb 20187:00 amRNSSynairgen starts dosing in Phase II COPD study
14th Dec 20177:00 amRNSUpdate on LOXL2 Programme&Pharmaxis Collaboration
8th Nov 20174:31 pmRNSHolding(s) in Company
27th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
27th Sep 20177:00 amRNSData update and clinical plan for COPD
13th Sep 201712:44 pmRNSHolding(s) in Company
6th Sep 20177:00 amRNSLOXL2 Inhibitor Update.
28th Jun 201712:41 pmRNSResult of AGM
5th Jun 20177:00 amRNSPosting of Annual Report and Notice of AGM
17th May 20177:00 amRNSPreliminary Results
27th Apr 20177:00 amRNSAZD9412 Update
27th Mar 20177:00 amRNSHolding(s) in Company
13th Mar 20173:10 pmRNSHolding(s) in Company
10th Mar 20178:34 amRNSAdditional Positive Data in Lung Fibrosis
17th Jan 20172:46 pmRNSHolding(s) in Company
13th Oct 201610:44 amRNSHolding(s) in Company
12th Oct 20167:00 amRNSAZD9412 Clinical Trial Update
22nd Sep 20167:00 amRNSInterim results for six months ended 30 June 2016
8th Sep 20167:00 amRNSNotice of Interim Results
14th Jun 201612:00 pmRNSResult of AGM
17th May 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Apr 20162:14 pmRNSHolding(s) in Company
23rd Mar 20167:00 amRNSExercise of Options
22nd Mar 20167:00 amRNSPositive LOXL2 results
22nd Mar 20167:00 amRNSPreliminary results for the year ended 31 Dec 2015
3rd Mar 20167:00 amRNSNotice of Preliminary Results
16th Nov 20154:11 pmRNSAdoption of FRS 101 - Reduced Disclosure Framework
13th Nov 20153:08 pmRNSHolding(s) in Company
13th Nov 201511:41 amRNSHolding(s) in Company
13th Nov 20157:00 amRNSHolding(s) in Company
12th Nov 20157:00 amRNSDirectors' Share Purchase
28th Oct 20157:00 amRNSGrant of options
16th Sep 20157:00 amRNSInterim Results
21st Aug 20157:00 amRNSNotice of Interim Results
5th Aug 20157:00 amRNSSynairgen announces research collaboration
22nd Jul 20157:00 amRNSAstraZeneca commences Phase II Trial
22nd Jun 20151:41 pmRNSResult of AGM
2nd Jun 20159:37 amRNSHolding(s) in Company
15th May 201511:04 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.